Abstract: Objectives and Aim: We performed a study on Seroprevalance of HBV among the patients attending a tertiary care hospital in India. Background: Globally, Hepatitis B is one of the most common infectious diseases. It is ranked by the WHO as one of the top ten killers. The virus is responsible for approximately 1.5 million deaths worldwide in each year, two thirds of which are attributable to primary Hepatocellular carcinoma following HBV infection. About 360 million people are estimated to be chronically infected with HBV. Methods: Out of 4648 serum samples submitted to the Department of Microbiology at JSS Hospital Mysuru during the study period of one year from January to December, 284 samples were positive for HBsAg by ELISA. Results: The seroprevalence of Hepatitis B infection in our study was 6%. Conclusions: The study showed a seropositivity of 6% in patients attending this tertiary care centre, because there is lack of awareness and health education, negligence. Stringent blood banking laws need to be introduced. NAAT screening is currently in use in most of the developed countries but not yet mandatory in India.
Introduction
Viral hepatitis due to Hepatitis B virus (HBV) is a major public health problem throughout the world affecting several hundreds of millions of people. It is a cause of considerable morbidity and mortality in human population from both acute infections and chronic squeal which include acute infection, chronic active hepatitis, cirrhosis and primary liver cancer. 1 Hepatitis B virus was recognized originally as the cause of serum hepatitis, the most common form of parenterally transmitted viral hepatitis, and an important cause of acute and chronic infection of the liver in many countries. More than one third of the world's population has been infected with HBV and WHO estimates that it results in 1 to 2 million deaths every year. The incubation period of hepatitis B is variable with a range of between 1 and 6 months. Acute hepatitis B infection is anicteric and asymptomatic most of the time, although a severe illness with jaundice can occur and acute liver failure may develop. The virus persists in about 10% of infected immunocompetent adults and in as many as 90% of infants infected perinatally, depending on the ethnic group of the mother. About 350 million people worldwide are persistent carriers of HBV. Liver damage is mediated by the cellular immune response of the host to the infected hepatocytes. Approximately 25% of all patients with chronic hepatitis will progress to cirrhosis and about 20 % of those with cirrhosis will develop Hepatocellular carcinoma. 2 Hepatocellular Carcinoma is one of the most common cancers worldwide. However the significance and magnitude of the problem vary from country to country. 3 As per WHO guidelines, Countries are classified on the basis of endemicity of hepatitis-B virus (HBV) infection into high (8% or more), intermediate (2-7%), or low (less than 2%) incidence countries. The prevalence of chronic HBV infection in India ranges from 2% to 10% as shown in different studies. India therefore comes under the intermediate to high endemicity category. India has approximately HBV carrier rate of 3.0% with a high prevalence rate in the tribal population. 3 With a population of more than 1.25 billion, India has more than 37 million HBV carriers and contributes a large proportion of the global HBV burden. While horizontal transmission in childhood appears to be a major route of transmission, the role of vertical transmission is probably underestimated 4 . Blood transfusion and unsafe therapeutic injections continue to be important modes of transmission of HBV. Liver biopsy, ultrasonography, CT abdomen and fibroscan were also done for these patients.
3) Tables and Figures
Cross sectional study Cross sectional study is the simplest form of an observational study. It is based on a single examination of a cross-section of population at one point in time-the results of which can be projected on the whole population provided the sampling has been done correctly. Cross sectional study is also known as "prevalence study". Cross-sectional studies are more useful for chronic diseases. It tells about the distribution of a disease in population rather than its aetiology.
Statistical methods Applied
Qualitative variables are expressed as proportions and 95% confidence interval (95% CI). Quantitative variables are expressed as mean and standard deviation. Chi square test is used to check the association of qualitative variables. In accordance with the prevalence of seropositivity the same number of controls were randomly selected and analysis done for association with risk factors using chi square test.
Contingency coefficient test (Cross tabs)
The Crosstabs procedure forms two-way and multiway tables and provides a variety of tests and measures of association for two-way tables. 
Results

Demographic characteristics
Out of 4648 serum samples submitted to the Department of Microbiology at JSS Hospital Mysuru during the study period of one year from January to December, 284 samples were positive for HBsAg by ELISA (Figure 1) .The patients for whom the samples were submitted formed the subjects of this study. Out of these 198 were Male (69.7%) and 86 were female (30.3%) ( figure 4 ). 
Figure 1: Prevalance of HBV
Demographic distribution
Discussion a. Seropositivity
The seroprevalence of Hepatitis B infection in our study was 6%. This may not necessarily represent the endemicity, magnitude in this part of the state, as ours is a tertiary care centre and significant no. of samples were from clinically suspected cases.The prevalence of Chronic HBV infection in different studies ranged from 2 to 10% (below 8%) as per literature survey. Therefore India has intermediate to high endemicity 6.
PragatiAbhimanyuBullee et al 7 in Yavatmal (Maharashtra), India found that the Seroprevalence of HBsAg positive was 1.57% while in healthy donors it was 0.87 %. The prevalence of HBsAg in the general population of Asia, Africa, Southern Europe and South America ranges from 2% to 20%.HBsAgseropositivity of 3-4% is reported in the Indian population.There is wide variation in the prevalence in different regions of the country with the highest prevalence in Andaman and Arunachal Pradesh 11 .Various studies across India reports HBsAgseroprevalence ranging Licensed Under Creative Commons Attribution CC BY from 1.6% to 5.7% in South India,3-6% in North India, and 2.97% in West Bengal. 10 The HBV seropositivity in our study was high in male (69.7%)as compared to female(30.3%)similar results were observed in another study conducted by AtulRukadikaret al, they found that seropositivity was high in male i.e., 73.39% than female 26.60%. 8 This could be due to greater exposure of male patients to the health care set up.Most of the patients infected with Hepatits B were in the age group of 31 to 50 years in our study, similar results were seen in study conducted by Prasad Bhate et al . 
Conclusion
1) The present cross sectional study titled "SEROPREVALANCE OF Hepatitis B virus (HBV) IN A TERTIARY CARE HOSPITAL" was undertaken in the Department of Microbiology, spanning over one year duration showed a seropositivity of 6% in patients attending this tertiary care centre. 2) Because there is lack of awareness and health education, negligence, the focus of primary prevention efforts should be safer blood supply in the developing world, safe injection practices in health care and other settings, and decreasing the number of people who initiate injection drug use. 3) Stringent blood banking laws need to be introduced. It is important to screen the blood donors to control the spread of HBV infection. The latest specific measure is the introduction of viral nucleic acid amplification test (NAAT). NAAT screening is currently in use in most of the developed countries but not yet mandatory in India. It detects viral genes rather than antibodies or antigens. NAAT will enable earlier detection of HBV. 4) Further studies need to be done on genotyping of large number of sample in order to determine the association with disease severity, progression and risk factor.
